MX2022000642A - Anticuerpos contra metalotioneina y su uso. - Google Patents
Anticuerpos contra metalotioneina y su uso.Info
- Publication number
- MX2022000642A MX2022000642A MX2022000642A MX2022000642A MX2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A MX 2022000642 A MX2022000642 A MX 2022000642A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies against
- metallothionein
- against metallothionein
- antibodies
- prediabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874340P | 2019-07-15 | 2019-07-15 | |
| PCT/US2020/042064 WO2021011608A1 (en) | 2019-07-15 | 2020-07-15 | Metallothionein antibodies and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000642A true MX2022000642A (es) | 2022-03-11 |
Family
ID=71895285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000642A MX2022000642A (es) | 2019-07-15 | 2020-07-15 | Anticuerpos contra metalotioneina y su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12466877B2 (https=) |
| EP (1) | EP3999531A1 (https=) |
| JP (1) | JP7669339B2 (https=) |
| KR (1) | KR20220034811A (https=) |
| CN (2) | CN114127105B (https=) |
| AU (1) | AU2020315367A1 (https=) |
| BR (1) | BR112022000705A2 (https=) |
| CA (1) | CA3144014A1 (https=) |
| IL (1) | IL289843A (https=) |
| MX (1) | MX2022000642A (https=) |
| PH (1) | PH12022550097A1 (https=) |
| WO (1) | WO2021011608A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121002061A (zh) * | 2023-01-12 | 2025-11-21 | 弗吉尼亚大学专利基金委员会 | 抗cith3抗体及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103201290B (zh) * | 2010-06-14 | 2016-09-28 | 莱克拉生物医学股份公司 | S100a4抗体及其治疗用途 |
| US20140141009A1 (en) * | 2011-07-08 | 2014-05-22 | Univeristy Of Connecticut | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| EP3740282B1 (en) * | 2018-01-17 | 2025-03-26 | University of Connecticut | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease |
-
2020
- 2020-07-15 AU AU2020315367A patent/AU2020315367A1/en active Pending
- 2020-07-15 EP EP20750116.4A patent/EP3999531A1/en active Pending
- 2020-07-15 BR BR112022000705A patent/BR112022000705A2/pt unknown
- 2020-07-15 US US17/625,476 patent/US12466877B2/en active Active
- 2020-07-15 CN CN202080051788.2A patent/CN114127105B/zh active Active
- 2020-07-15 WO PCT/US2020/042064 patent/WO2021011608A1/en not_active Ceased
- 2020-07-15 KR KR1020227003374A patent/KR20220034811A/ko active Pending
- 2020-07-15 MX MX2022000642A patent/MX2022000642A/es unknown
- 2020-07-15 CN CN202411420348.6A patent/CN119285765A/zh active Pending
- 2020-07-15 JP JP2022502219A patent/JP7669339B2/ja active Active
- 2020-07-15 PH PH1/2022/550097A patent/PH12022550097A1/en unknown
- 2020-07-15 CA CA3144014A patent/CA3144014A1/en active Pending
-
2022
- 2022-01-13 IL IL289843A patent/IL289843A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022550097A1 (en) | 2022-11-21 |
| CN119285765A (zh) | 2025-01-10 |
| AU2020315367A1 (en) | 2022-02-03 |
| US20220306731A1 (en) | 2022-09-29 |
| JP2022542805A (ja) | 2022-10-07 |
| JP7669339B2 (ja) | 2025-04-28 |
| BR112022000705A2 (pt) | 2022-03-22 |
| IL289843A (en) | 2022-03-01 |
| WO2021011608A1 (en) | 2021-01-21 |
| EP3999531A1 (en) | 2022-05-25 |
| CN114127105B (zh) | 2024-10-29 |
| CA3144014A1 (en) | 2021-01-21 |
| US12466877B2 (en) | 2025-11-11 |
| CN114127105A (zh) | 2022-03-01 |
| KR20220034811A (ko) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| CO2020009625A2 (es) | Inhibidor de fap | |
| CL2021002769A1 (es) | Anticuerpos de unión a vista (divisional solicitud n° 201902610) | |
| MX2020009758A (es) | Producto combinado de inhibidor de bcl-2 o inhibidor dual de bcl-2/bcl-xl e inhibidor de btk y uso de este en la prevencion y/o tratamiento de enfermedades. | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| CL2022001722A1 (es) | Derivados carboxi con propiedades antiinflamatorias | |
| MX374501B (es) | Formulaciones de anticuerpos de her2 subcutáneas. | |
| EA202091672A1 (ru) | Стероиды и их антитело-конъюгаты | |
| EP3885406A4 (en) | Composition and stretched body | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2025001913A1 (es) | Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso. | |
| CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
| MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| IL286467A (en) | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof | |
| UY34988A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso | |
| CO2022003156A2 (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso | |
| MX2020002823A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| EA202192101A1 (ru) | Соединения и их применение | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| WO2018183182A8 (en) | Methods and compositions for reduction of immunogenicity | |
| MX2019012051A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. |